Tvardi publishes new preclinical ulcerative colitis data for STAT3 inhibitor TTI-101 in Int J Mol Sci

Bitget2026/09/24 12:00

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Tvardi Therapeutics disclosed newly published preclinical ulcerative colitis data supporting its STAT3 inhibitor program.
Results have already been presented via journal publication, not a future conference readout.
The study showed the oral drug concentrated in the colon and broadly reduced disease biology linked to inflammation and abnormal tissue growth.
Findings strengthen the rationale to advance TTI-109, a next-generation STAT3 inhibitor, toward ulcerative colitis development.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609240800PRIMZONEFULLFEED9833097) on September 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tvardi publishes new preclinical ulcerative colitis data for STAT3 inhibitor TTI-101 in Int J Mol Sci

You may also like

Crypto prices